Pharmacokinetics of mavacoxib in New Zealand White rabbits (Oryctolagus cuniculus)
American Journal of Veterinary Research · 2023
DOI: 10.2460/ajvr.22.11.0196 ↗Kurz gefasst
Fachartikel in der Zeitschrift American Journal of Veterinary Research, 2023. Verfasst von Sarah E Wilson und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS. Hauptthemen laut MEDLINE: Pyrazoles. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 15 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
OBJECTIVES To characterize the pharmacokinetics of a single oral dose (6 mg/kg) of mavacoxib in New Zealand White rabbits ( Oryctolagus cuniculus ) and to characterize any clinicopathologic effects with this medication and dose. ANIMALS Six healthy, 4-month-old New Zealand White rabbits (3 male, 3 female). PROCEDURES Before drug administration, clinicopathologic samples were collected for baseline data (CBC, serum biochemical analyses, and urinalysis including urine protein-to-creatinine ratio). All 6 rabbits received a single oral dose (6 mg/kg) of mavacoxib. Clinicopathologic samples were collected at set time intervals to compare with the baseline. Plasma mavacoxib concentrations were determined using liquid chromatography with mass spectrometry, and pharmacokinetic analysis was performed using non-compartmental methods. RESULTS After a single oral dose, the maximum plasma concentration (C max ; mean, range) was 854 (713–1040) ng/mL, the time to C max (t max ) was 0.36 (0.17–0.50) days, the area under the curve from 0 to the last measured time point (AUC 0-last ) was 2000 (1765–2307) days*ng/mL, the terminal half-life (t 1/2 ) was 1.63 (1.30–2.26) days, and the terminal rate constant (λ z ) was 0.42 (0.31–0.53) days. All results for CBCs, serum biochemical analyses, urinalyses, and urine protein-to-creatinine ratios remained within published normal reference intervals. CLINICAL RELEVANCE This study determined that plasma concentrations reached target levels of 400 ng/mL for 48 hours in 3/6 rabbits at 6 mg/kg PO. In the remaining 3/6 rabbits, the plasma concentrations were 343–389 ng/mL at 48 hours, which is below the target concentration. Further research is needed to make a dosing recommendation, including a pharmacodynamic study and investigating pharmacokinetics at different doses and multiple doses.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Clinical Sciences, College of Veterinary Medicine, Kansas State University, Manhattan, KS.
- Evolution Veterinary Specialists, Lakewood, CO.
- Institute of Computational Comparative Medicine and Department of Anatomy and Physiology, College of Veterinary Medicine, Kansas State University, Manhattan, KS.
Zitieren
APA
Wilson, S. E., Carpenter, J. W., Gardhouse, S., & KuKanich, B. (2023). Pharmacokinetics of mavacoxib in New Zealand White rabbits (Oryctolagus cuniculus). American Journal of Veterinary Research. https://doi.org/10.2460/ajvr.22.11.0196
Vancouver
Wilson SE, Carpenter JW, Gardhouse S, KuKanich B. Pharmacokinetics of mavacoxib in New Zealand White rabbits (Oryctolagus cuniculus). American Journal of Veterinary Research. 2023. doi:10.2460/ajvr.22.11.0196
BibTeX
@article{Wilson2023,
author = {Wilson, Sarah E and Carpenter, James W and Gardhouse, Sara and KuKanich, Butch},
title = {Pharmacokinetics of mavacoxib in New Zealand White rabbits (Oryctolagus cuniculus)},
journal = {American Journal of Veterinary Research},
year = {2023},
doi = {10.2460/ajvr.22.11.0196}
}
EUVIMED